Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 13/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807906 | 0.82 | SMN1; SMN2 (0.40) | NPSR1ALDH1A1HSD17B10MEN1HPGD | |
| SCHEMBL808229 | 0.79 | SIGMAR1 (0.32) | — | |
| SCHEMBL10287560 | 0.78 | HDAC4 (0.33) | — | |
| SCHEMBL807994 | 0.77 | SIGMAR1 (0.31) | — | |
| SCHEMBL10287187 | 0.76 | ALDH1A1 (0.45) | NPSR1ALDH1A1HSD17B10HPGDKMT2A | |
| SCHEMBL807920 | 0.76 | SIGMAR1 (0.33) | — | |
| SCHEMBL808333 | 0.76 | NPC1 (0.37) | ALDH1A1MEN1KMT2AKDM4EHTT | |
| SCHEMBL807976 | 0.75 | SIGMAR1 (0.31) | — | |
| SCHEMBL808221 | 0.75 | SIGMAR1 (0.32) | — | |
| SCHEMBL808224 | 0.74 | SIGMAR1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |